Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 73 recruiting now official registry

Cervical Cancer clinical trials

73 of 151 indexed Cervical Cancer trials are currently recruiting.

151 US clinical trials · 73 currently recruiting

Cervical Cancer is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.

The research picture

Cervical Cancer has 151 registered US clinical trials, 73 of them open to new participants right now, about 48% of the total.

73
recruiting participants now
48%
of trials open to enrollment
8
in Phase 3–4 (later-stage)
11
top sponsor: M.D. Anderson Cancer Center
Phase 148Phase 230Phase 37Phase 41

Active & Recent Trials

151 total, page 2 of 4

RECRUITING Phase 2 55 participants

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

University of Oklahoma

NCT05512208

RECRUITING NA 54 participants

Image-Guided Gynecologic Brachytherapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02993900

RECRUITING Phase 2 50 participants

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Memorial Sloan Kettering Cancer Center

NCT06925724

RECRUITING NA 50 participants

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

Medical College of Wisconsin

NCT07227077

RECRUITING Phase 1 48 participants

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Orano Med

NCT05283330

RECRUITING Phase 2 46 participants

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Precigen

NCT06157151

RECRUITING Phase 1 40 participants

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

NCT04038619

RECRUITING Phase 2 40 participants

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

M.D. Anderson Cancer Center

NCT05475171

RECRUITING Phase 2 35 participants

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Georgetown University

NCT04865887

RECRUITING Phase 1 32 participants

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06315257

RECRUITING Phase 2 32 participants

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

NCT06677190

RECRUITING NA 31 participants

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

University Health Network, Toronto

NCT04016389

RECRUITING Phase 1 30 participants

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Christian Hinrichs

NCT05483491

RECRUITING Phase 1 30 participants

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

University of Arizona

NCT06814496

RECRUITING Phase 2 30 participants

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

University of Texas Southwestern Medical Center

NCT06266338

RECRUITING 30 participants

Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment

UNC Lineberger Comprehensive Cancer Center

NCT04743674

RECRUITING Phase 1 27 participants

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America

NCT06943521

RECRUITING Phase 2 25 participants

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Abramson Cancer Center at Penn Medicine

NCT05758688

RECRUITING 20 participants

Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy

University of California, San Diego

NCT07121543

RECRUITING Phase 2 20 participants

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Christian Hinrichs

NCT05686226

RECRUITING Phase 2 20 participants

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Yale University

NCT05838521

RECRUITING 20 participants

Detecting HPV DNA in Anal and Cervical Cancers

University of Chicago

NCT04857528

RECRUITING Phase 1 9 participants

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Radiopharm Theranostics

NCT05799274

ACTIVE NOT RECRUITING NA 8,000 participants

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2

The University of Texas Health Science Center, Houston

NCT06082882

ACTIVE NOT RECRUITING Phase 1 1,410 participants

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Klus Pharma

NCT04152499

ACTIVE NOT RECRUITING 1,150 participants

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

TScan Therapeutics

NCT05812027

ACTIVE NOT RECRUITING Phase 1 840 participants

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

TScan Therapeutics

NCT05973487

ACTIVE NOT RECRUITING NA 360 participants

Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)

H. Lee Moffitt Cancer Center and Research Institute

NCT05645146

ACTIVE NOT RECRUITING NA 279 participants

Sexual Health Empowerment for Women's Health

University of Kansas Medical Center

NCT03984695

ACTIVE NOT RECRUITING Phase 1 256 participants

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

AbbVie

NCT05527184

ACTIVE NOT RECRUITING Phase 1 214 participants

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Seagen, a wholly owned subsidiary of Pfizer

NCT03786081

ACTIVE NOT RECRUITING Phase 2 212 participants

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Agenus

NCT03894215

ACTIVE NOT RECRUITING Phase 1 144 participants

A Study of ADRX-0706 in Select Advanced Solid Tumors

Adcentrx Therapeutics

NCT06036121

ACTIVE NOT RECRUITING Phase 1 130 participants

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals

NCT05215574

ACTIVE NOT RECRUITING Phase 1 120 participants

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Qurient Co.

NCT05438420

ACTIVE NOT RECRUITING NA 111 participants

Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement

Baylor College of Medicine

NCT06577220

ACTIVE NOT RECRUITING Phase 1 72 participants

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

NCT05238883

ACTIVE NOT RECRUITING Phase 1 71 participants

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals

NCT05311618

ACTIVE NOT RECRUITING Phase 2 66 participants

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Meghan Shea

NCT06238635

ACTIVE NOT RECRUITING Phase 1 63 participants

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co.

NCT04432857

ACTIVE NOT RECRUITING Phase 1 55 participants

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

National Cancer Institute (NCI)

NCT04708470

ACTIVE NOT RECRUITING Phase 1 51 participants

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

National Cancer Institute (NCI)

NCT04287868

ACTIVE NOT RECRUITING Phase 1 42 participants

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

Memorial Sloan Kettering Cancer Center

NCT02285192

ACTIVE NOT RECRUITING Phase 2 40 participants

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio

NCT03228667

ACTIVE NOT RECRUITING Phase 1 40 participants

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Arcus Biosciences

NCT05891171

ACTIVE NOT RECRUITING Phase 1 39 participants

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Cancer Institute (NCI)

NCT04432597

ACTIVE NOT RECRUITING NA 30 participants

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

Rutgers, The State University of New Jersey

NCT05220033

ACTIVE NOT RECRUITING Phase 2 21 participants

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT03614949

ACTIVE NOT RECRUITING Early Phase 1 20 participants

Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR

M.D. Anderson Cancer Center

NCT05047913

ACTIVE NOT RECRUITING Phase 2 18 participants

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

M.D. Anderson Cancer Center

NCT05063916

← Previous Page 2 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 48
Phase 2 30
Phase 3 7
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Cervical Cancer Trial Landscape

151 indexed Cervical Cancer studies · 73 recruiting (48%).

Phase mix: 8 late (III/IV) vs 78 early (I/II).

Top sponsor: M.D. Anderson Cancer Center (11 trials), 9 others listed. 50 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Cervical Cancer?

PlainTrial tracks 151 US clinical trials for Cervical Cancer, of which 73 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Cervical Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.